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Abstract
Background: Conflicting results have been recently reported evaluating the relationship between pneumococcal
vaccination and the risk of thrombotic vascular events. This study assessed the clinical effectiveness of the 23-
valent polysaccharide pneumococcal vaccine (PPV23) against acute myocardial infarction and ischaemic stroke in
older adults.
Methods: Population-based prospective cohort study conducted from December 1, 2008 until November 30, 2009,
including all individuals ≥ 60 years-old assigned to nine Primary Care Centres in Tarragona, Spain (N = 27,204
individuals). Primary outcomes were hospitalisation for acute myocardial infarction and/or ischaemic stroke. All
cases were validated by checking clinical records. The association between pneumococcal vaccination and the risk
of each outcome was evaluated by Multivariable Cox proportional-hazard models (adjusted by age, sex, influenza
vaccine status, presence of comorbidities and cardiovascular risk factors).
Results: Cohort members were followed for a total of 26,444 person-years, of which 34% were for vaccinated subjects.
Overall incidence rates (per 1000 person-years) were 4.9 for myocardial infarction and 4.6 for ischaemic stroke. In the
multivariable analysis, vaccination was associated with a marginally significant 35% lower risk of stroke (hazard ratio
[HR]: 0.65; 95% confidence interval [CI]: 0.42-0.99; p = 0.046). We found no evidence for an association between
pneumococcal vaccination and reduced risk of myocardial infarction (HR: 0.83; 95% CI: 0.56-1.22; p =0 . 3 4 7 ) .
Conclusions: Our data supports a benefit of PPV23 against ischaemic stroke among the general population over
60 years, suggesting a possible protective role of pneumococcal vaccination against some acute thrombotic
events.
Background
The 23-valent polysaccharide pneumococcal vaccine
(PPV23) is recommended for high-risk and older adults
[1-3], although its effectiveness remains unclear [4,5].
Numerous studies have demo n s t r a t e dt h a tP P V 2 3p r o -
vides considerable protection against invasive pneumo-
c o c c a ld i s e a s e[ 2 , 3 ] ,w h i l eap o s s i b l ep r o t e c t i v ee f f e c t
against other clinically relevant outcomes as commu-
nity-acquired pneumonia is controversial [4-6].
In recent years, considering that some studies have
reported an increasing risk of thrombotic events among
patients with pneumonia [7-9], it has been suggested
that pneumococcal vaccination would protect patients
from coronary and/or cerebrovascular attacks. However,
three studies using health databases to evaluate the
effectiveness of pneumococcal vaccination in preventing
myocardial infarction and/or stroke have recently been
published with conflicting results [10-12].
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nation on cardiovascular prevention could have
immense clinical implications, prospective studies,
which will determine whether the protective effect of
vaccination is real or not are greatly needed.
In Catalonia, a region in the northeast of Spain with a
population of seven million people, a publicly funded
anti-pneumococcal vaccination programme for all indi-
viduals 60 years or older (with or without risk factors)
began in October 2002. Since then, the PPV23 is offered
when the patients came to the primary care centres dur-
ing the annual influenza vaccination campaigns or in
any other visit throughout the year [13]. Revaccination
at 5 years is only recommended for people under 65
years.
Following this, we designed a large prospective cohort
study, known as CAPAMIS, with the major aim of eval-
uating the potential role of the PPV23 in cardiovascular
prevention among the general population over 60 years
[14]. The CAPAMIS study was planned for 3-year fol-
low-up. In this study, we have evaluated the clinical
effectiveness of PPV23 in reducing the risk of hospitali-
sation for CAP, acute myocardial infarction and ischae-
mic stroke in a first-time analysis at one-year follow-up.
Methods
Design, setting and study population
Study design has been extensively described elsewhere
[14]. In brief, this is a closed population-based prospec-
tive cohort study including 27,204 individuals 60 years or
older assigned to nine primary care centers in the Health
Region of Tarragona (a mixed residential-industrial
urban area in the Mediterranean coast of Catalonia,
Spain). The study was approved by the ethical committee
of the Catalonian Health Institute (P09/49) and was con-
ducted in accordance with the general principles for
observational studies. In this first-time report, we analyse
the primary end-points resulting from the first year of
survey. Cohort members were followed since the start of
the study (December 1, 2008) until the occurrence of any
event, change in pneumococcal vaccination status, disen-
rollment from the primary care center, death, or until the
end of first 12-month follow-up (November 30, 2009).
Data sources
All participating primary care centers have a computer-
ized clinical record system that includes administrative
data, medical conditions, prescriptions, laboratory
results and diagnosis associated with hospital and outpa-
tient visits. This electronic clinical record system was
used to classify cohort members by their pneumococcal
vaccination status as well as to identify comorbidities or
underlying conditions and establish baseline characteris-
tics of the cohort at study entry. The hospital diagnosis
discharge databases of the two reference hospitals in the
study area (Joan XXIII and Santa Tecla), coded accord-
ing to the International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9) were used to
identify study events.
Outcomes
The primary outcomes were hospitalisation for commu-
nity acquired pneumonia, acute myocardial infarction,
ischaemic stroke and death from any cause. Outcomes
were initially identified on the basis of listed ICD-9 diag-
nosis codes for pneumonia (480 to 487.0), myocardial
infarction (410) and ischaemic stroke (433, 434, 436 and
437). Cases were only definitively included if, on conclu-
sion of the medical record review, the physician
reviewer (two specialist family physicians previously
trained) verified the diagnosis according to criteria men-
tioned below.
Pneumonia was defined when a new radiological infil-
trate was identified with one major criteria (cough,
expectoration or fever) or two minor criteria (dyspnea,
pleuritic pain, altered mental status, pulmonary consoli-
dation on auscultation and leukocytosis) [14].
Acute Myocardial Infarction was defined as a detec-
tion of rise and/or fall in cardiac biomarkers together
with at least one of the following: symptoms of ischae-
mia, ECG changes indicative of new ischaemia (new ST-
T changes, new left bundle branch block and/or devel-
opment of pathological Q waves) and/or imaging evi-
dence of new loss of viable myocardium or new regional
wall motion abnormality [15].
Ischaemic stroke was considered when a patient
rapidly developed signs of focal or global disturbance of
cerebral function lasting more than 24 h (unless inter-
rupted by surgery or death), with no apparent nonvascu-
lar cause and a neuro image showing an ischaemic brain
lesion [16].
Vaccination history
Pneumococcal vaccination status was determined by a
review of the primary care centers’ electronic clinical
records, which contain specially designated fields for
pneumococcal and influenza vaccinations. We assumed
that information in the computerized clinical records
system (working since 1999) was complete, so a subject
was considered as unvaccinated when a vaccination was
not recorded. Cohort members were classified as vacci-
nated against pneumococcus if they had received at
least one dose of PPV23 in the last 60 months before
study start.
Statistical analysis
Incidence rates were calculated as person-years, consid-
ering in the denominator the sum of the persons-time
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Baseline characteristics according to pneumococcal vac-
cination status were compared using Chi-squared test.
Cox proportional hazards models were used to assess
the association between having received the pneumococ-
cal vaccine and the time to the first outcome [17]. The
final models were adjusted for significant and confoun-
der variables.
The following variables were considered in all the
initial models: age, sex, number of outpatient visits to
family physician in 12-months before study start (< 3,3-
5,6-9,≥10), influenza vaccination in prior autumn, his-
tory of coronary artery disease (myocardial infarction or
angina), history of stroke, history of chronic heart dis-
ease (congestive heart failure, hypertensive heart disease,
cardiomyopathy, valvulopathy, cardiac dilatation or ven-
tricular hypertrophy), chronic pulmonary disease
(chronic bronchitis, emphysema and asthma), hyperten-
sion, hypercholesterolemia, obesity, diabetes mellitus,
smoking status (non-smoker, quit, current), alcoholism,
chronic severe liver disease(chronic viral hepatitis, alco-
holic hepatitis and cirrhosis), chronic severe nephropa-
thy (nephrotic syndrome, renal failure, dialysis or
transplantation), cancer (solid organ or haematological
neoplasia), dementia and nursing-home residence. Age,
sex and influenza vaccine status were judged epidemio-
logically relevant variables, being included in all the final
models. The variables were time-invariant and defined
at study entry.
The authors checked for confounders and multicoli-
nearity among the independent variables. The propor-
tional hazard assumptions were assessed by adding the
covariate by time interactions to the model and plotting
the scaled and smoothed Schoenfeld residuals obtained
from main effects model, where possible. All results
were expressed with 95% confidence intervals (CIs). Sta-
tistical significance was set at p < 0.05 (two-tailed). The
analyses were performed using Stata/SE version 11.1 for
Windows (StataCorp. LP).
Results
The 27,204 cohort members were observed for a total of
26,444 person-years, of which 8,847 (33.5%) person-
years had received PPV23 in prior 5 years.
Mean age of study subjects when study started was
71.7 (SD: 8.6) years-old and 44.6% were male. Vacci-
nated group were significantly older, had more outpati-
ent visits, had a much higher proportion of influenza
vaccination and had more comorbidities than the unvac-
cinated group (Table 1).
During the 12-month follow-up, a validated episode of
community acquired pneumonia was observed in 207
cases, a validated episode of acute myocardial infarction
was observed in 130 cases and a validated episode of
ischaemic stroke was observed in 121 cases. There was
an incidence (per 1000 person-years) of 7.9 (95% CI:
6.9-9.0) for pneumonia, 4.9 (95% CI: 4.2-5.9) for myo-
cardial infarction and 4.6 (95% CI: 3.8-5.5) for ischaemic
stroke. Of the 27,204 cohort members, 840 died during
study period (39 deaths from myocardial infarction/
stroke). All-cause mortality rate was 31.8 per 1000 per-
son-years (95% CI: 29.7-34.0), whereas specific mortality
rates was 1.5 per 1000 (95% CI: 1.1-2.0) for myocardial
infarction/stroke.
In the unadjusted analysis, we observed 63 episodes of
pneumonia in 8,824 vaccinated person-years (7.1 per
1000 person-years) compared with 144 events in 17,546
unvaccinated person-years (8.2 per 1000 person-years).
For myocardial infarction, there were 41 episodes of
myocardial infarction in 8,830 vaccinated person-years
(4.6 per 1000 person-years) compared with 89 events in
17,565 unvaccinated person-years (5.1 per 1000 person-
years). For stroke, there were 30 events in 8,835 vacci-
nated person-years (3.4 per 1000 person-years) com-
pared with 91 events in 17,559 unvaccinated person-
years (5.2 per 1000 person-years). The unadjusted all-
cause mortality rates were 26.1 and 34.6 per 1000 per-
son-years among vaccinated and unvaccinated subjects,
respectively.
In the multivariable analyses, despite vaccinated peo-
ple had lower incidence rates than unvaccinated people,
we found no evidence for an association between pneu-
mococcal vaccination and risk of pneumonia (adjusted
hazard ratio [HR]: 0.85; 95% CI: 0.62-1.15; p = 0.287) or
myocardial infarction (adjusted HR: 0.83; 95% CI: 0.56-
1.22; p = 0.347), but vaccination emerged significantly
associated with a reduced risk of ischaemic stroke
(adjusted HR: 0.65; 95% CI: 0.42-0.99; p = 0.048).
Although vaccinated subjects had lower all-cause mor-
tality rates than unvaccinated subjects in the unadjusted
analysis, vaccination was not associated with reduced
risk of all-cause mortality in the multivariable analysis
(adjusted HR: 0.88; 95% CI: 0.75-1.03; p = 0.118).
Table 2 shows the values of unadjusted and adjusted
analyses for the different outcomes. The covariate pneu-
mococcal vaccine has proportional hazards in all the
models. Footnotes in table indicate those predictor vari-
ables statistically significant (p < 0.05) or confounders in
the final multivariable models.
In a separate analysis including only immunocompe-
tent people n = 24,278 persons, the results did not sub-
stantially vary. Among these subjects, with multivariable
adjustment, pneumococcal vaccination did not emerge
significantly effective against pneumonia (adjusted HR:
0.84; 95% CI: 0.59-1.19; p = 0.319), myocardial infarction
(adjusted HR: 0.83; 95% CI: 0.55-1.25; p = 0.363) or
death from any cause (adjusted HR: 0.84; 95% CI: 0.68-
1.02; p = 0.083), but it was associated with a significant
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0.63; 95% CI: 0.40-0.99; p = 0.049).
Analyses restricted to persons with possible immuno-
compromise (n = 2,926 subjects) showed, in general,
poor results. Among these subjects, we did not observe
any significant protective effect of vaccination against
pneumonia (adjusted HR: 0.92; 95% CI: 0.47-1.81; p =
0.811), myocardial infarction (adjusted HR: 0.81; 95%
CI: 0.25-2.66; p = 0.732), ischaemic stroke (adjusted
HR: 0.75; 95% CI: 0.23-2.41; p = 0.628) or death from
any cause (adjusted HR: 0.99; 95% CI: 0.75-1.30; p =
0.941).
Table 1 Baseline Characteristics of 27,204 cohort members according to their Pneumococcal vaccination status before
the study started
Characteristic Unvaccinated
a
(n = 18,223)
Vaccinated
(n = 8,981)
p value
b Total
N = 27,204
No. (%)
Age group, yrs
c
60-69 8522 (46.8) 3879 (43.2) < 0.001 12401 (45.6)
70-79 5833 (32.0) 3451 (38.4) 9284 (34.1)
≥ 80 3868 (21.2) 1651 (18.4) 5519 (20.3)
Sex, Male 8074 (44.3) 4063 (45.2) 0.145 12137 (44.6)
No. of outpatient visits during previous 12 months
d
[0-2] 4886 (26.8) 1168 (13) < 0.001 6054(22.3)
[3-5] 4183 (23.0) 2207 (24.6) 6390(23.5)
[6-9] 4338 (23.8) 2569 (28.6) 6907(25.4)
≥10 4816 (26.4) 3037 (33.8) 7853(28.9)
Influenza vaccination in previous Autumn 6997 (38.4) 7371 (82.1) < 0.001 14368 (52.8)
History of coronary artery disease 1122 (6.2) 611 (6.8) 0.040 1733 (6.4)
History of stroke 808 (4.4) 486 (5.4) < 0.001 1294 (4.8)
Chronic pulmonary disease 1421 (7.8) 742 (8.3) 0.183 2163 (8.0)
Chronic heart disease
e 2084 (11.4) 1324 (14.7) < 0.001 3408 (12.5)
Chronic liver disease 383 (2.1) 239 (2.7) 0.004 622 (2.3)
Chronic nephropathy 44 (2.4) 214 (2.4) 0.786 658 (2.4)
Diabetes mellitus 3713 (20.4) 2192 (24.4) < 0.001 5905 (21.7)
Hypertension 9245 (50.7) 5304 (59.1) < 0.001 14549 (53.5)
Hypercholesterolemia 6351 (34.9) 3611 (40.2) < 0.001 9962 (36.6)
Obesity (BMI > 30) 5089 (27.9) 3150 (35.1) < 0.001 8239 (30.3)
Smoking status
Non-smoker 12855 (70.5) 5826 (64.9) < 0.001 18681(68.7)
Quit 3479 (19.1) 2248 (25.0) 5727(21.1)
Current 1889 (10,4) 907 (10.1) 2796(10.3)
Alcoholism 655 (3.6) 340 (3.8) 0.429 995 (3.7)
Cancer 1297 (7.1) 703 (7.8) 0.035 2000 (7.4)
Immunosuppressive medication 772 (4.2) 425 (4.7) 0.061 1197 (4.4)
Immunocompromise
f 1921 (10.5) 1005 (11.2) 0.104 2926 (10.8)
Dementia 535 (2.9) 266 (3.0) 0.905 801 (2.9)
Nursing-home residence 265 (1.5) 110 (1.2) 0.127 375 (1.4)
a An amount of 6,179 individuals were classified as non-immunized because they had received the PPV23 more than 60 months before study start.
b p values were calculated with chi-square test.
c The mean ages of the unvaccinated and vaccinated subjects were 71.5 years (Standard Deviation, SD: 8.9) and 72.0 years (SD: 7.8) respectively. Mean ageo f
overall study subjects was 71.7 years (SD: 8.6).
d The mean number of outpatient visits during previous 12 months were 7.1 (SD: 6.7) in unvaccinated and 8.4 (SD: 6.3) in vaccinated subjects. Mean number of
visits among the overall study population was 7.5 (SD: 6.6).
e It includes congestive heart failure, hypertensive heart disease, cardiomyopathy, valvulopathy, cardiac dilatation or ventricular hypertrophy.
f Immunocompromise was a composite variable defined by the presence of any one of the following: cancer (solid organ or haematological neoplasia), chronic
severe nephropathy (nephrotic syndrome, renal failure, dialysis or transplantation), anatomical or functional asplenia, immunodeficiency (including AIDS), and
long-term corticosteroid therapy (20 mg/day of prednisone) or another immunosuppressive medication.
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ary artery disease (n = 1,733 persons) or stroke (n =
1,294 persons), did not substantially vary the results.
In the analyses including exclusively 25,471 subjects
without history of coronary artery disease, we observed
30 episodes of myocardial infarction in 8,236 vaccinated
person-years (3.6 per 1000 person-years) compared with
48 events in 16,510 unvaccinated person-years (2.9 per
1000 person-years). This means that pneumococcal vac-
cination was not associated with significant reductions
in the risk of myocardial infarction in the unadjusted
analysis (HR: 1.25; 95% CI: 0.79-1.98; p =0 . 3 4 4 )n e i t h e r
in the multivariable analysis (adjusted HR: 1.12; 95% CI:
0.69-1.82; p = 0.660).
Among the 25,910 subjects without history of prior
stroke, we observed 13 episodes of ischaemic stroke in
8,366 vaccinated person-years (1.6 per 1000 person-
year) compared with 60 events among 16,810 unvacci-
nated person-years (3.6 per 1000 person-years), which
pointed to a significant reduction in the risk of ischae-
mic stroke among vaccinated subjects in the unadjusted
analysis (HR: 0.43; 95% CI: 0.24-0.79; p = 0.006). Multi-
variable analysis confirmed this association (adjusted
HR: 0.46; 95% CI: 0.25-0.85; p = 0.013).
In the total study population, according to incidence
data among vaccinated and unvaccinated subjects for
the different outcomes, number needed to vaccinate for
preventing one case of ischaemic stroke was 560 vacci-
nations (95% CI: 295 to 5,649). If we consider pneumo-
nia and myocardial infarction, although the results did
not reach statistical significance, number needed to vac-
cinate were 938 and 2,365 vaccinations, respectively
(Table 3).
Discussion
We undertook a large prospective population-based
study to evaluate the controversial effectiveness of the
PPV23 against myocardial infarction and stroke. To our
knowledge, this is the first prospective study using vali-
dated clinical data that provides population based
assessment of pneumococcal vaccination effectiveness
against cardiovascular events. Although we did not con-
duct a randomized controlled trial, the large size of our
study population together with adjustment for important
covariables in the multivariable analysis, provides an
adequate basis for assessing this major public health
issue in the general population over 60 years (main tar-
get population where PPV23 is recommended).
Table 2 Incidence and Risk of hospitalization for community acquired pneumonia (CAP), acute myocardial infarction
(AMI), ischaemic stroke and death from any cause among patients 60 years or older in relation to pneumococcal-
vaccination status
a
CAP AMI Ischaemic Stroke Death from
any cause
Number of event
Vaccinated 63 41 30 231
Unvaccinated 144 89 91 609
Unadjusted incidence rate per 1000 person-years
Vaccinated 7.1 (5.6-9.1) 4.6 (3.4-6.3) 3.4 (2.4-4.9) 26.1 (23.0-29.7)
Unvaccinated 8.2 (7.0-9.7) 5.1 (4.1-6.2) 5.2 (4.2-6.4) 34.6 (32.0-37.5)
Unadjusted hazard ratio for all subjects 0.87 0.91 0.66 0.75
(95% CI) (0.65-1.17) (0.63-1.32) (0.43-0.99) (0.65-0.88)
p value 0.368 0.637 0.046 < 0.001
Age, gender adjusted hazard ratio 0.87 0.90 0.66 0.79
(95% CI) (0.65-1.17) (0.62-1.30) (0.44-1.00) (0.68-0.91)
p value 0.354 0.582 0.049 0.002
bc de
Multivariate hazard ratio 0.85 0.83 0.65 0.88
(95% CI) (0.62-1.15) (0.56-1.22) (0.42-0.99) (0.75-1.03)
p value 0.287 0.347 0.048 0.118
a Hazard ratios were for vaccinated subjects as compared with unvaccinated subjects.
b Adjusted for age, sex, number of outpatient visits in prior year, influenza vaccination in prior year, chronic pulmonary disease, chronic heart disease, smoking
and nursing-home resident.
c Adjusted for age, sex, number of outpatient visits in prior year, influenza vaccination in prior year, history of coronary artery disease, chronic heart disease,
diabetes mellitus, hypercholesterolemia, smoking (confounder) and nursing-home resident.
d Adjusted for age, sex, number of outpatient visits in prior year, influenza vaccination in prior year, history of coronary artery disease, history of stroke, smoking
(confounder) and nursing-home resident.
e Adjusted for age, sex, number of outpatient visits in prior year, influenza vaccination in prior year, chronic pulmonary disease, chronic heart disease, diabetes
mellitus, cancer, chronic nephropaty, dementia, hypertension, hypercholesterolemia, obesity, smoking, and nursing home-resident.
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cant reduction in the risk of ischaemic stroke, suggesting
a possible protective role of vaccination against some
acute thrombotic events. Considering the total study
population, pneumococcal vaccination was associated
with a 35% (95% CI: 1% to 58%) reduction in the adjusted
risk of ischaemic stroke. This result seems to be robust
considering that this significant protective effect remains
when people with history of prior stroke are excluded
from the analysis. The observed protective effect of vacci-
nation against myocardial infarction (17%) was weaker
and did not reach statistical significance (-22% to 44%).
Prior studies that have tried to examine this question
have reported conflicting results [10-12,18]. An earlier
case-control study that included 335 case patients with
myocardial infarction and 199 control subjects reported
a non significant protective effect of PPV23 against
myocardial infarction (odds ratio [OR]: 0.89 (95% CI:
0.60-1.33) [18]. In a Canadian hospital-based case-con-
trol study, 999 case patients who had been admitted for
treatment of myocardial infarction were compared with
3,996 control patients reporting that cases were less
likely than controls to have received PPV23 (7.1% vs
11.6%; adjusted OR: 0.53; 95% CI: 0.40-0.70) [10].
Importantly, the study population only included persons
at risk for myocardial infarction (persons with hyperten-
sion, diabetes mellitus and/or dyslipidemia) and “healthy
user” bias possibly occurred in selecting controls [19,20].
In a recent retrospective large cohort study involving
84,170 men aged 45 to 69 years in California, Tseng et
al. [11] examined the relationship between pneumococ-
cal vaccination and risk of myocardial infarction and
stroke, concluding that receipt of pneumococcal vaccine
was not associated with subsequent reduced risk of both
events. However, some major methodological distinc-
tions may explain the different results observed in the
present study and the Tseng’sr e p o r t .T h i ss t u d yu s e d
validated clinical data to establish outcome events rather
than billing data used in Tseng’s report. In addition, this
study includes all population over 60 years, whereas the
study by Tseng et al. only included men 45-69 years-old
without prior history of coronary artery disease or
stroke. In addition, as it was noted,[21,22] it is not clear
whether the protective effect of pneumococcal vaccina-
tion against vascular events in individuals aged 65 years
or older (main target group for vaccination) was prop-
erly assessed in Tseng’s report given that 78% of sample
size were men less than 65 years-old. In fact, the
adjusted Hazard Ratios for acute myocardial infarction
(HR: 0.89; 95% CI: 0.80-1.01; p = 0.10) and stroke (HR:
0.85; 95% CI: 0.70-1.03; p = 0.10) observed in Tseng’s
report, although not reaching conventional significance
levels, suggested that there might be a protective effect
of pneumococcal vaccination against vascular events in
people over 65 years-old [11,22].
In other large observational study using health data-
bases in Hong Kong, Hung et al. [12] have recently
reported significant lower risks of acute myocardial
infarction (HR: 0.52; 95% CI: 0.38-0.71) and ischaemic
stroke (HR: 0.67; 95% CI: 0.54-0.83) among elderly per-
sons who received dual vaccination with PPV23 and
influenza vaccine. Our estimates of protective effect of
vaccination against ischaemic stroke is essentially similar
to data observed in the Hung’s report.
Multiple mechanisms could contribute to the potential
cardiovascular protective effect of pneumococcal vacci-
nation. Possible direct effects include a reduction risk
for pathogenic cross reaction antibodies induced by per-
sistent pneumococcal antigens. Animal experiments
have shown that pneumococcal vaccination reduces the
extent of atherosclerotic lesions, and it has been
hypothesized that antibodies directed against pneumoco-
cus would also cross react with oxidized low-density
lipoprotein and impede the formation of foam cells [23].
The role of acute infection in triggering acute coronary
or cerebrovascular events would be complex and multi-
factorial (e.g., increased inflammatory activity, pro-
thrombotic conditions, and biomechanical stress on the
arteries, disrupting and triggering thrombosis in a preex-
isting advanced artery lesion) [24].
Table 3 Numbers needed to vaccinate for preventing one case of community acquired pneumonia, acute myocardial
infarction or ischaemic stroke by pneumococcal vaccination in people 60 years or older
Outcome Attributable Risk
per 1000 person/year
Number Need to Vaccinate
AR
a 95% CI
b NNV
c 95% CI
(lower to higher
d)
Community acquired pneumonia 1.067 -1.139 to 3.327 938 306 to -878
Acute myocardial infarction 0.423 -1.341 to 2.187 2,365 458 to -746
Ischaemic Stroke 1.788 0.177 to 3.399 560 295 to 5649
a Attributable Risk = incidence rate difference between unvaccinated and vaccinated subjects.
b CI denotes confidence interval.
c NNV is the number needed to vaccinate for preventing one case and is estimated as 1/AR.
d The negative numbers in the high limit of confidence interval indicate that NNV tends to infinite and it is not statistically significant.
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troversy about PPV efficacy against pneumonia exists
[4-6]. The last Cochrane Review Reported a pooled vac-
cine efficacy of 29% (95% CI: 3% to 48%) against all-
cause pneumonia. Our results showing a non-statisti-
cally significant 15% reduction in the adjusted risk of
pneumonia among vaccinated subjects fits with data
reported in Cochrane review and other meta-analysis
and they do not exclude the possibility of a little, but
non insignificant effect against pneumonia.
A major strength of this study is that it was population-
based and included all target people for pneumococcal
vaccination in a well defined geographical area. Other
important strengths were the prospective design, the vali-
dation of outcome events by checking clinical records
that protects against biases related to recall and the use
of survival analysis methods to estimate vaccine effective-
ness adjusted by important covariables such as age, sex,
influenza vaccine status, presence of main comorbidities
and cardiovascular risk factors. Two possible confound-
ing factors (dietary habits and physical activity) were not
measured in the present study. However, given multicoli-
nearity exists between these factors and other multiple
factors measured in our study (e.g., body mass index,
blood pressure and cholesterol level), which were consid-
ered in the multivariable analyses, is seems unlikely that
these two factors would introduce a systematic bias on
the vaccination effectiveness estimates.
Given the large size of our study population, many
statistically significant differences appear when compar-
ing vaccinated and unvaccinated groups, but most of
them were not substantial. The authors performed mul-
tivariable adjustment for potential confounders to
account for these differences in the statistical analysis.
However, as with all observational studies, the possible
influence of residual confounding or a healthy user
effect on the estimates of vaccine effectiveness cannot
be completely excluded considering that vaccination was
non-randomized.
T h er e l a t i v e l yh i g hp r o p o r t i o no fu n v a c c i n a t e ds u b -
jects in the present cohort study (67%) is largely due to
criteria used to define cohort members as adequately
immunized against pneumococcus (at least one dose of
PPV23 within 5 years prior study start). According this
restrictive definition, many elderly individuals (without
criteria for revaccination) were classified as unvaccinated
because they had received PPV23 more than five years
before study start and this fact contributed to the rela-
tively high size of the unvaccinated group. If we con-
sider all individuals who had received a dose of PPV23
at any time, the proportion of cohort members never
vaccinated against pneumococcus would be only 44%,
which fits with data reported in other studies assessing
PPV effectiveness [6].
On other hand, it must be noted that criteria used to
classify individuals as adequately immunized against
pneumococcus (at least one dose of PPV23 in prior 60
months before study start) can impact the results evalu-
ating vaccination effectiveness. Although it has been
reported that antibody level declines 3-5 years after vac-
cination, it is possible that a protective effect of PPV23
(if exists) could remain over time.
Future analyses (involving a considerable higher num-
ber of person-years followed) should evaluate the effects
of the vaccine according to time elapsed since vaccina-
tion. These analyses should investigate the possible vac-
cination effectiveness among those individuals who
received the PPV23 in prior 6-10 years as compared
with those who received the vaccine in prior 5 years or
those who were never vaccinated.
Given the demonstrated efficacy of PPV23 against inva-
sive pneumococcal disease, commencing new Randomized
Controlled Trials in populations at risk would create ethi-
cal difficulties. Thus, prospective cohort studies using vali-
dated clinical data are an acceptable alternative to estimate
vaccine effectiveness against different clinically relevant
outcomes among different populations at risk.
Conclusions
We emphasise that this study should be considered as
an interim analysis. A further detailed analysis, including
more person-years of observation, should provide accu-
rate population-based data on incidence of myocardial
infarction and stroke in different subsets of the popula-
tion in order to establish, if confirms, the magnitude of
vaccination effectiveness in primary and/or secondary
cardiovascular prevention.
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